SCHEMBL15710355

SCHEMBL15710355

NCCCCCCn1ccnc1[N+](=O)[O-]

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.56
CA1 P00915 5/20 0.56
CA2 P00918 5/20 0.56
CA9 Q16790 5/20 0.56
LMNA P02545 1/20 0.45
THRB P10828 1/20 0.45
CYP2C19 P33261 1/20 0.45
TYMP P19971 3/20 0.44
KMT2A Q03164 1/20 0.44
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
OPRK1 P41145 1/20 0.41
EGFR P00533 8/20 0.39
TLR8 Q9NR97 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28572545 1.00 CA12 (0.56) CA12CA1CA2CA9LMNA
SCHEMBL28588942 1.00 CA12 (0.56) CA12CA1CA2CA9LMNA
SCHEMBL17783197 1.00 CA12 (0.56) CA12CA1CA2CA9LMNA
SCHEMBL4357511 0.98 CA12 (0.57) CA12CA1CA2CA9LMNA
SCHEMBL4360078 0.94 CA12 (0.58) CA12CA1CA2CA9LMNA
Hydrochloric Acid SCHEMBL31250585 0.92 CA12 (0.57) CA12CA1CA2CA9LMNA
Trifluoroacetic Acid SCHEMBL29174409 0.88 CA12 (0.46) CA12CA1CA2CA9LMNA
SCHEMBL8431954 0.87 CA12 (0.61) CA12CA1CA2CA9LMNA
Trifluoroacetic Acid SCHEMBL29174403 0.87 CA12 (0.47) CA12CA1CA2CA9LMNA
SCHEMBL15323854 0.86 CA12 (0.54) CA12CA1CA2CA9LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116942615-A Nanoparticle for co-delivering paclitaxel and gemcitabine as well as preparation method and application thereof 湖南师范大学 2023-10-27 CN claimed
EP-3285750-B1 GLUCOSE-RESPONSIVE INSULIN DELIVERY SYSTEM USING HYPOXIA-SENSITIVE NANOCOMPOSITES UNIV NORTH CAROLINA STATE (US) 2020-10-21 EP claimed
WO-2025133654-A1 NEW CRYPTATE-TYPE (BICYCLIC) CHELATORS AND THEIR USE AS LIGANDS FOR MN(II)-BASED MRI CONTRAST AGENTS, 52MN-BASED PET DIAGNOSTIC AGENTS, AND 64/67CU(II)-ISOTOPE-BASED PET DIAGNOSTIC AND THERAPEUTIC AGENTS DEBRECENI EGYETEM (HU) 2025-06-26 WO disclosed
CN-116942615-A Nanoparticle for co-delivering paclitaxel and gemcitabine as well as preparation method and application thereof 湖南师范大学 2023-10-27 CN disclosed
CN-113350489-A Glucose responsive insulin delivery system using hypoxia sensitive nanocomposite material 北卡罗来纳州立大学 2021-09-07 CN disclosed
CN-107530296-B Glucose responsive insulin delivery system using hypoxia sensitive nanocomposite material 北卡罗来纳州立大学 2021-06-22 CN disclosed
CN-108778248-A METHODS AND COMPOSITIONS RELATED TO PHYSIOLOGICALLY RESPONSIVE MICRONEEDLE DELIVERY SYSTEMS 北卡罗来纳州立大学 2018-11-09 CN disclosed
CN-108395489-A A kind of 2- nitroimidazoles-cysteine-alginate material and preparation method thereof 华侨大学 2018-08-14 CN disclosed
CN-107530296-A Glucose responsive insulin delivery system using hypoxia sensitive nanocomposite material 北卡罗来纳州立大学 2018-01-02 CN disclosed
US-9084806-B2 Hypoxia-responsive nanoparticle for therapy and imaging of hypoxia-involving diseases Research & Business Foundation Sungkyunkwan University (KR) 2015-07-21 US disclosed
US-9084806-B2 Hypoxia-responsive nanoparticle for therapy and imaging of hypoxia-involving diseases Research & Business Foundation Sungkyunkwan University (KR) 2015-07-21 US disclosed
US-9084806-B2 Hypoxia-responsive nanoparticle for therapy and imaging of hypoxia-involving diseases Research & Business Foundation Sungkyunkwan University (KR) 2015-07-21 US disclosed
US-9044519-B2 Radiotracer precursor for imaging of hypoxic tissue, radiotracer, and method for preparing the same Atomic Energy Council—Institute of Nuclear Energy Research (TW) 2015-06-02 US disclosed
US-20140371434-A1 RADIOTRACER PRECURSOR FOR IMAGING OF HYPOXIC TISSUE, RADIOTRACER, AND METHOD FOR PREPARING THE SAME ATOMIC ENERGY COUNCIL-INSTTITUTE OF NUCLEAR ENERGY RESEARCH (TW) 2014-12-18 US disclosed
US-20140141084-A1 HYPOXIA-RESPONSIVE NANOPARTICLE FOR THERAPY AND IMAGING OF HYPOXIA-INVOLVING DISEASES Research & Business Foundation Sungkyunkwan University (KR) 2014-05-22 US disclosed
US-20140141084-A1 HYPOXIA-RESPONSIVE NANOPARTICLE FOR THERAPY AND IMAGING OF HYPOXIA-INVOLVING DISEASES Research & Business Foundation Sungkyunkwan University (KR) 2014-05-22 US disclosed
US-20140141084-A1 HYPOXIA-RESPONSIVE NANOPARTICLE FOR THERAPY AND IMAGING OF HYPOXIA-INVOLVING DISEASES Research & Business Foundation Sungkyunkwan University (KR) 2014-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371434-A1 RADIOTRACER PRECURSOR FOR IMAGING OF HYPOXIC TISSUE, RADIOTRACER, AND METHOD FOR PREPARING THE SAME HIF1A, HIF1AN, HYOU1 CA12 228/4885CA1 214/4885CA2 280/4885
US-20140141084-A1 HYPOXIA-RESPONSIVE NANOPARTICLE FOR THERAPY AND IMAGING OF HYPOXIA-INVOLVING DISEASES HIF1A, HIF1AN, HYOU1 CA12 14/4885CA1 41/4885CA2 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.